



FACT SHEET

Value Fund

As of June 30, 2022



Portfolio Manager:
Mark Finn

Managed Fund Since:
2009

Joined Firm:
1990

FUND INFORMATION

| | |
|---|--------------------------------|
| Symbol | TRVLX |
| CUSIP | 779578103 |
| Inception Date of Fund | September 30, 1994 |
| Benchmark | Russell 1000 Value Index |
| Expense Information (as of the most recent Prospectus)* | 0.67% (Gross) 0.65% (Net) |
| Fiscal Year End | December 31 |
| Total Annual Operating Expenses per \$1,000 | \$6.70 (Gross) \$6.50 (Net) |
| 12B-1 Fee | – |
| Portfolio Holdings Turnover† | 107.0% |
| Total Assets (all share classes) | \$31,027,109,026 |
| Percent of Portfolio in Cash | 2.6% |
| Beta (5 Years) | 0.94 |

* The Fund operates under a contractual expense limitation that expires on April 30, 2023.

† Portfolio Turnover represents 1 year period ending 12/31/21.

INVESTMENT OBJECTIVE AND STRATEGY

The fund seeks to provide long-term capital appreciation by investing in common stocks believed to be undervalued. Income is a secondary objective.

Focus on “bargain” stocks that offer an opportunity for capital appreciation as other investors recognize the company’s real value.

Intensive in-house research identifies undervalued stocks by considering, among other factors, key financial ratios:

- Price/earnings
- Price/book value
- Price/cash flow

BENEFITS AND RISKS

Exposure to the capital appreciation potential of undervalued stocks.


Potential for reduced downside risk relative to the overall market.

Potentially lower price appreciation compared with a growth fund.

Possibility that a stock judged to be undervalued is actually appropriately priced.

CUMULATIVE RETURNS

Growth of \$10,000



PERFORMANCE

(NAV, total return)

| | Three Months | Year-to-Date | One Year | Annualized | | | |
|--------------------------|--------------|--------------|----------|-------------|------------|-----------|---------------|
| | | | | Three Years | Five Years | Ten Years | Fifteen Years |
| Value Fund | -12.27% | -14.71% | -6.90% | 9.51% | 8.93% | 12.12% | 7.38% |
| Russell 1000 Value Index | -12.21 | -12.86 | -6.82 | 6.87 | 7.17 | 10.50 | 6.10 |
| S&P 500 Index | -16.10 | -19.96 | -10.62 | 10.60 | 11.31 | 12.96 | 8.54 |

Performance data quoted represents past performance and is not a reliable indicator of future performance. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. To obtain the most recent month-end performance, visit troweprice.com. Consider the investment objectives, risks, and charges and expenses carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, call 1-855-405-6488 or visit troweprice.com. Read it carefully. The average annual total return figures reflect the reinvestment of dividends and capital gains, if any. The fund(s) may have other share classes available that offer different investment minimums and fees. See the prospectus for details. For Sourcing Information, please see Additional Disclosures.

TOP 10 ISSUERS

| | Industry | % of Fund | % of Russell 1000 Value Index |
|-----------------------------|------------------------------|-----------|-------------------------------|
| Becton, Dickinson & Company | Health Care Equip & Supplies | 3.9% | 0.4% |
| Elevance Health | Health Care Providers & Svcs | 3.3 | 0.5 |
| Southern Company | Electric Utilities | 3.2 | 0.4 |
| JPMorgan Chase | Banks | 2.9 | 1.9 |
| TotalEnergies | Oil, Gas & Consumable Fuels | 2.9 | 0.0 |
| Microsoft | Software | 2.7 | 0.0 |
| Johnson & Johnson | Pharmaceuticals | 2.7 | 2.6 |
| AstraZeneca | Pharmaceuticals | 2.6 | 0.0 |
| AbbVie | Biotechnology | 2.6 | 0.0 |
| Chubb | Insurance | 2.5 | 0.5 |

MORNINGSTAR™

Overall Morningstar Rating™

Morningstar Category™

Large Value

Rated against 1,145 Large Value funds, as of 6/30/2022, based on risk-adjusted total return. Ratings are determined monthly and subject to change. The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) Morningstar Rating metrics. **Past performance is no guarantee of future results.**

SECTOR DIVERSIFICATION

| | Health Care | Financials | Utilities | Cons Stpls | Info Tech | Indust & Bus Svcs | Cons Disc | Energy | Materials | Comm Svcs | Real Estate |
|--------------------------|-------------|-------------|------------|------------|--------------|-------------------|-------------|-------------|-------------|-------------|-------------|
| Value Fund | 26.0% | 14.2% | 12.9% | 10.3% | 9.1% | 8.9% | 5.0% | 3.8% | 2.7% | 2.3% | 2.2% |
| Russell 1000 Value Index | 17.2 | 19.5 | 6.0 | 7.3 | 8.8 | 10.1 | 5.8 | 7.2 | 4.2 | 8.8 | 5.1 |
| Over/Underweight | 8.7 | -5.3 | 6.9 | 3.0 | 0.3 | -1.2 | -0.8 | -3.4 | -1.5 | -6.5 | -2.9 |
| S&P 500 Index | 15.1 | 10.8 | 3.1 | 7.0 | 26.7 | 7.9 | 10.5 | 4.4 | 2.6 | 8.9 | 2.9 |
| Over/Underweight | 10.8 | 3.4 | 9.8 | 3.4 | -17.6 | 1.0 | -5.5 | -0.6 | 0.1 | -6.6 | -0.8 |

For Sourcing Information, please see Additional Disclosures.

Not FDIC-Insured. May lose value. No bank guarantee.

INVEST WITH CONFIDENCE®

Definitions

Beta: A measure of market risk of an investment option that shows how responsive the investment is to a given market index, such as the Standard & Poor's 500 Index. By definition, the beta of the benchmark is 1.00. An investment with a beta of 1.10 is expected to perform 10% better than the index in up markets and 10% worse in down markets. Usually, higher betas represent riskier investments. Figures are calculated using monthly data and are net of fees.

Additional Disclosures

Morningstar rated the fund 4, 4, and 5 stars among 1,145, 1,077 and 779 Large Value funds for the 3-, 5-, and 10-year periods (as applicable) ending 6/30/2022, respectively. The Morningstar Rating™ for funds, or "star rating", is calculated for funds with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star.

Source for Morningstar data: © 2022 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance is no guarantee of future results.**

London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2022. FTSE Russell is a trading name of certain of the LSE Group companies. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

The S&P 500 Index is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ("SPDJ") and has been licensed for use by T. Rowe Price. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"). This product is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates, or none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P 500 Index.

Unless otherwise noted, index returns are shown with gross dividends reinvested.

The information shown does not reflect any ETFs that may be held in the portfolio.

T. Rowe Price uses the MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting. T. Rowe Price will adhere to all future updates to GICS for prospective reporting.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc, ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by T. Rowe Price. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any or such standard or classification. Without limiting any or the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Diversification exhibits may not add to 100% due to exclusion or inclusion of cash.

Certain numbers in this report may not equal stated totals due to rounding. Unless otherwise stated, data is as of the report date.

© 2022 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/ or apart, trademarks of T. Rowe Price Group, Inc.

T. Rowe Price Investment Services, Inc., Distributor.

202105-1662624